Aromatase inhibitors, efficacy and metabolic risk in the treatment of postmenopausal women with early breast cancer.
about
Optimal management of cancer treatment-induced bone loss: considerations for elderly patients.Pharmacogenomics of third-generation aromatase inhibitors.Phase I trial of the androgen receptor modulator CR1447 in breast cancer.The implications of genetic variation for the pharmacokinetics and pharmacodynamics of aromatase inhibitors.Association of estrogen receptor alpha (ERα) gene polymorphisms with endometrial thickness and lipid profile in women with breast cancer treated with aromatase inhibitors
P2860
Aromatase inhibitors, efficacy and metabolic risk in the treatment of postmenopausal women with early breast cancer.
description
article científic
@ca
article scientifique
@fr
articolo scientifico
@it
artigo científico
@pt
bilimsel makale
@tr
scientific article published on January 2008
@en
vedecký článok
@sk
vetenskaplig artikel
@sv
videnskabelig artikel
@da
vědecký článek
@cs
name
Aromatase inhibitors, efficacy ...... omen with early breast cancer.
@en
Aromatase inhibitors, efficacy ...... omen with early breast cancer.
@nl
type
label
Aromatase inhibitors, efficacy ...... omen with early breast cancer.
@en
Aromatase inhibitors, efficacy ...... omen with early breast cancer.
@nl
prefLabel
Aromatase inhibitors, efficacy ...... omen with early breast cancer.
@en
Aromatase inhibitors, efficacy ...... omen with early breast cancer.
@nl
P2860
P921
P356
P1476
Aromatase inhibitors, efficacy ...... omen with early breast cancer.
@en
P2093
Roberto Petrioli
Stefano Gonnelli
P2860
P304
P356
10.2147/CIA.S3466
P407
P577
2008-01-01T00:00:00Z